ATE484506T1 - Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren - Google Patents

Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren

Info

Publication number: ATE484506T1
Authority: AT; Austria
Prior art keywords: sulfonamides; bombesine; modulators; receptor subtype; substituted diazepine
Prior art date: 2006-12-11

Application number

AT07862652T

Other languages

English (en)

Inventor

Robert K Baker

Linda L Chang

Marc Chioda

Harry R Chobanian

Ying-Duo Gao

Yan Guo

Linus S Lin

Ping Liu

Ravi P Nargund

Kathleen M Rupprecht

Shouwu Miao

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-11

Filing date

2007-12-07

Publication date

2010-10-15

2007-12-07 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE484506T1 publication Critical patent/ATE484506T1/de

Links

-1 DIAZEPINE SULFONAMIDES Chemical class 0.000 title 1
229940124530 sulfonamide Drugs 0.000 title 1
102100028628 Bombesin receptor subtype-3 Human genes 0.000 abstract 2
108010063504 bombesin receptor subtype 3 Proteins 0.000 abstract 2
239000003446 ligand Substances 0.000 abstract 2
108010073466 Bombesin Receptors Proteins 0.000 abstract 1
101000695054 Homo sapiens Bombesin receptor subtype-3 Proteins 0.000 abstract 1
KUFVCQHJVFZQNY-UHFFFAOYSA-N N1N=C(C=CC=C1)S(=O)(=O)N Chemical class N1N=C(C=CC=C1)S(=O)(=O)N KUFVCQHJVFZQNY-UHFFFAOYSA-N 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Neurology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Immunology (AREA)

AT07862652T 2006-12-11 2007-12-07 Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren ATE484506T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87437606P	2006-12-11	2006-12-11
PCT/US2007/025104 WO2008073311A2 (en)	2006-12-11	2007-12-07	Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators

Publications (1)

Publication Number	Publication Date
ATE484506T1 true ATE484506T1 (de)	2010-10-15

Family

ID=39512271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07862652T ATE484506T1 (de)	2006-12-11	2007-12-07	Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren

Country Status (9)

Country	Link
US (1)	US8153626B2 (de)
EP (1)	EP2102201B1 (de)
JP (1)	JP5313161B2 (de)
CN (1)	CN101605788A (de)
AT (1)	ATE484506T1 (de)
AU (1)	AU2007332867B2 (de)
CA (1)	CA2671482C (de)
DE (1)	DE602007009873D1 (de)
WO (1)	WO2008073311A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012064268A1 (en) *	2010-11-08	2012-05-18	Albireo Ab	Ibat inhibitors for treatment of metabolic disorders and related conditions
CA2837036A1 (en) *	2011-07-04	2013-01-10	Unilever Plc	Method for reduction of energy intake by consuming an aerated product at least three times a day
EP2567959B1 (de)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
MX389242B (es) *	2015-06-15	2025-03-20	Nmd Pharma As	Compuestos para su uso en el tratamiento de trastornos neuromusculares
US11730714B2 (en)	2017-12-14	2023-08-22	Nmd Pharma A/S	Compounds for the treatment of neuromuscular disorders
US11591284B2 (en)	2017-12-14	2023-02-28	Nmd Pharma A/S	Compounds for the treatment of neuromuscular disorders
US11147788B2 (en)	2017-12-14	2021-10-19	Nmd Pharma A/S	Compounds for the treatment of neuromuscular disorders
US12440477B2 (en)	2017-12-14	2025-10-14	Nmd Pharma A/S	Compounds for the treatment of neuromuscular disorders
CN116987040B (zh) *	2023-06-21	2025-09-23	中国中医科学院中药研究所	二苯并二氮杂卓衍生物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5326776A (en)	1992-03-02	1994-07-05	Abbott Laboratories	Angiotensin II receptor antagonists
JPH07243068A (ja)	1994-03-08	1995-09-19	Murata:Kk	金属表面の電解処理方法
IL124557A0 (en) *	1995-12-15	1998-12-06	Novo Nordisk As	Compositions for reducing blood glucose and/or inhibiting the activity of cgrp
AU730224B2 (en)	1996-12-23	2001-03-01	Du Pont Pharmaceuticals Company	Nitrogen containing heteroaromatics as factor Xa inhibitors
EP1042299A1 (de)	1997-12-22	2000-10-11	Du Pont Pharmaceuticals Company	Stickstoffenthaltende heteroaromaten mit ortho-substituierten p1 gruppen als faktor-xa-inhibitoren
DE10224844A1 (de) *	2002-06-05	2004-01-08	Solvay Pharmaceuticals Gmbh	Nicht-peptidische BRS-3-Agonisten
JPWO2004007464A1 (ja)	2002-07-10	2005-11-10	住友製薬株式会社	イミダゾール誘導体
AU2003290120A1 (en)	2002-11-19	2004-06-15	Galderma Research & Development, S.N.C.	Biaromatic compounds which activate PPAR-Gama type receptors, and use thereof in cosmetic or pharmaceutical compositions
PL376736A1 (pl)	2002-11-25	2006-01-09	Galderma Research & Development, S.N.C.	Nowe związki diaromatyczne, które aktywują receptor typu PPAR<$Egamma> i ich zastosowanie w kompozycjach kosmetycznych lub farmaceutycznych
ZA200504898B (en)	2002-12-20	2006-11-29	Pharmacia Corp	Acyclic pyrazole compounds
CA2514363A1 (en)	2003-02-12	2004-08-26	Transtech Pharma, Inc.	Substituted azole derivatives as therapeutic agents
US7141596B2 (en)	2003-10-08	2006-11-28	Incyte Corporation	Inhibitors of proteins that bind phosphorylated molecules
GB0328796D0 (en) *	2003-12-12	2004-01-14	Biofocus Plc	Compounds which interact with the G-protein coupled receptor family
CA2551909C (en)	2004-02-12	2011-10-11	Transtech Pharma, Inc.	Substituted azole derivatives, compositions, and methods of use
GB0403578D0 (en) *	2004-02-18	2004-03-24	Biofocus Discovery Ltd	Compounds which interact with the G-protein coupled receptor family
AP2006003768A0 (en) *	2004-05-25	2006-10-31	Pfizer Prod Inc	TetraazabenzoÄeÜazulene derivatives and analogs tehereof
IT1362675B (it) *	2005-03-15	2009-06-25	Menarini Internat Operations Luxembourg Sa	N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche

2007
- 2007-12-07 CN CNA2007800511664A patent/CN101605788A/zh active Pending
- 2007-12-07 DE DE602007009873T patent/DE602007009873D1/de active Active
- 2007-12-07 AT AT07862652T patent/ATE484506T1/de not_active IP Right Cessation
- 2007-12-07 JP JP2009541314A patent/JP5313161B2/ja not_active Expired - Fee Related
- 2007-12-07 CA CA2671482A patent/CA2671482C/en not_active Expired - Fee Related
- 2007-12-07 WO PCT/US2007/025104 patent/WO2008073311A2/en not_active Ceased
- 2007-12-07 AU AU2007332867A patent/AU2007332867B2/en not_active Ceased
- 2007-12-07 EP EP07862652A patent/EP2102201B1/de not_active Not-in-force
- 2007-12-07 US US12/517,836 patent/US8153626B2/en active Active

Also Published As

Publication number	Publication date
AU2007332867B2 (en)	2012-02-16
AU2007332867A1 (en)	2008-06-19
EP2102201A2 (de)	2009-09-23
US20100317645A1 (en)	2010-12-16
DE602007009873D1 (de)	2010-11-25
CA2671482A1 (en)	2008-06-19
WO2008073311A2 (en)	2008-06-19
CN101605788A (zh)	2009-12-16
EP2102201B1 (de)	2010-10-13
WO2008073311A3 (en)	2008-10-30
JP5313161B2 (ja)	2013-10-09
JP2010512387A (ja)	2010-04-22
CA2671482C (en)	2012-01-24
US8153626B2 (en)	2012-04-10

Legal Events

Date	Code	Title	Description
2011-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
NO20084792L (no)	2009-01-13	Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer
ATE484506T1 (de)	2010-10-15	Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
DE602007007594D1 (de)	2010-08-19	Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
DE602007008868D1 (de)	2010-10-14	Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
MX2009004112A (es)	2009-05-11	Imidazoles sustituidos como moduladores del receptor de bombesina subtipo-3.
WO2008008286A3 (en)	2008-04-24	Substituted pyrazoles as ghrelin receptor antagonists
TW200745126A (en)	2007-12-16	Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
GEP20146101B (en)	2014-05-27	Pyridine and pyrazine derivatives as protein kinase modulators
EA200901166A1 (ru)	2010-04-30	Соединения и композиции в качестве модуляторов активности gpr 119
MY149855A (en)	2013-10-31	Benzimidazole derivatives and their use for modulating the gaba? receptor complex
AU2008317057A8 (en)	2014-02-13	Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
NO20082011L (no)	2008-04-28	Acylerte spiropiperidinderivater som melanocortin-4-reseptormodulatorer
MX2010003117A (es)	2010-04-01	Compuestos y composiciones como moduladores de la actividad de gpr119.
EA201100062A1 (ru)	2011-08-30	Соединения и способы модулирования рецепторов, связанных с белком g
DE602005009748D1 (de)	2008-10-23	3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
JO2645B1 (en)	2012-06-17	Vehicles
MX2009003981A (es)	2009-04-27	Agentes moduladores del receptor de calcio.
MY142409A (en)	2010-11-30	Novel cannabinoid 1 or cannabinoid 2 receptor modulators, pharmaceutical compositions containing them, and process for their preparation
MX2010006206A (es)	2011-03-04	Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2009071690A3 (de)	2009-07-23	5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2009006812A (es)	2009-07-02	Moduladores del receptor c3a y metodos de uso de los mismos.
WO2009051718A3 (en)	2009-06-11	Calcium receptor modulating agents
MX2009013197A (es)	2010-04-27	Derivados terapeuticos de pirazolonaftiridina.
IL189974A0 (en)	2008-08-07	Benzimidazole derivatives and their use for modulating the gabaa receptor complex
EA201070637A1 (ru)	2010-12-30	Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н